Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients

Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Grygiel-Górniak, Bogna, Shaikh, Osama, Kumar, Nikita Niranjan, Hsu, Shao Heng, Samborski, Włodzimierz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2021
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436792/
https://www.ncbi.nlm.nih.gov/pubmed/34538956
http://dx.doi.org/10.5114/reum.2021.108554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436792/
https://www.ncbi.nlm.nih.gov/pubmed/34538956
http://dx.doi.org/10.5114/reum.2021.108554

Ejemplares similares